Novartis’ Cosentyx shows quality of life benefits for plaque psoriasis patients

Novartis has announced the findings of a new study that demonstrate the quality of life benefits that the drug Cosentyx can provide for people with plaque psoriasis.

Results from the SCULPTURE study have been presented at the 2018 American Academy of Dermatology Annual Meeting, showing that two-thirds of moderate-to-severe plaque psoriasis patients treated with Cosentyx reported no impact of skin disease on their quality of life after five years.

This makes Cosentyx the first and only fully human interleukin-17A inhibitor therapy that has been shown to offer sustained skin clearance rates at five years in patients over the course of a psoriasis phase III study.

Shreeram Aradhye, chief medical officer and global head of medical affairs at Novartis Pharmaceuticals, said: "We are excited by this new evidence, showing two-thirds of psoriasis patients reporting no impact on their quality of life at five years when treated with Cosentyx, and the possibilities this offers patients."

The drug has been approved for the treatment of ankylosing spondylitis, psoriatic arthritis and plaque psoriasis, and has been prescribed to more than 140,000 patients worldwide since launch.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.